JohnMRichartMD
Oncology • Saint Louis, MOAssociate Professor, Internal Medicine, St Louis University School of Medicine
Dr. Richart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3660 Vista
Saint Louis, MO 63110Phone+1 314-577-8854Fax+1 314-773-1167
Education & Training
SSM Health/Saint Louis University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
University of Missouri-Columbia School of MedicineClass of 1993
Certifications & Licensure
MO State Medical License 1996 - 2025
KS State Medical License 1999 - 2020
IL State Medical License 1999 - 2011- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma Start of enrollment: 2013 Sep 01
Publications & Presentations
PubMed
- 1 citationsImmunotherapy-Induced Auto-Splenectomy in a Patient of Malignant Melanoma.Syed Ehsanullah, Azharuddin Muhammad, Syed Hasan, John M Richart
Cureus. 2022-05-01 - 18 citationsOxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient ObesityNiloufar Khojandi, Lindsey M. Kuehm, Alexander Piening, Maureen J. Donlin, Eddy C. Hsueh
Cancer Immunology Research. 2021-02-01 - 99 citationsTherapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna Pradyuman Patel
Journal for Immunotherapy of Cancer. 2019-02-18
Press Mentions
New Therapy Improves Life Span in Melanoma Patients with Brain MetastasesJuly 31st, 2013
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
